Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
FULC Stock Chart & Stats
$10.14
-$0.39(-7.98%)
At close: 4:00 PM EST
$10.14
-$0.39(-7.98%)
Day’s Range― - ―
52-Week Range$2.32 - $15.74
Previous CloseN/A
Volume345.04K
Average Volume (3M)764.07K
Market Cap
$668.94M
Enterprise Value$382.26M
Total Cash (Recent Filing)$200.65M
Total Debt (Recent Filing)$7.01M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Feb 26, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding65,970,290
10 Day Avg. Volume991,518
30 Day Avg. Volume764,071
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)1.20
Price to Sales (P/S)3.64
P/FCF Ratio-116.72
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-571.39
Enterprise Value/Ebitda-5.28
Forecast
1Y Price Target
$17.00Price Target Upside67.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development MomentumPhase 1b PIONEER results reduced program risk by demonstrating consistent biological rationale and a favorable safety profile, with the 20 mg dose showing stronger hemoglobin F increases and tolerability versus lower doses.
Pipeline DiversificationPreclinical activity for EED inhibitor FTX-6274 in prostate cancer models expands commercial optionality beyond benign hematology and could create additional value if clinical translation occurs.
Trial Enrollment And Patient AccessFull enrollment in PIONEER cohorts and initiation of an open-label extension support continued safety and durability data collection and could broaden patient access and physician uptake.
Bears Say
Analyst Valuation PressureAn analyst reiteration of an Underperform rating with a low price objective signals constrained near-term upside and may weigh on investor sentiment and stock momentum.
Efficacy ConcernsObserved hemoglobin response was softer than some expectations and was lower than a prior cohort, raising questions about the magnitude of clinical benefit needed for broad adoption.
Regulatory And Launch UncertaintyDependence on FDA discretion for label expansion and a revised launch timeline introduce regulatory and timing risk that could delay commercial rollout and revenue realization.
Fulcrum Therapeutics News
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.31 and its highest was $15.74 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Fulcrum Therapeutics’s market cap is $668.94M.
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 37 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Oct 29, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.294 by -$0.016.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 65,970,290 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.294. Following the earnings report the stock price went down -6.4%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Currently, no hedge funds are holding shares in FULC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fulcrum Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (67.65% Upside)
$17.00 (67.65% Upside)
Hedge Fund Trend
Decreased
By 879.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $58.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
261.23%
12-Months-Change
Fundamentals
Return on Equity
-31.21%
Trailing 12-Months
Asset Growth
-22.99%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FULC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the clinical development of pociredir for sickle cell disease, with promising trial results and a strong financial position. Despite a decrease in cash reserves and continued net losses, the company's achievements and future plans position it well for further advancements.View all FULC earnings summariesFULC Stock 12 Month Forecast
Average Price Target
$17.00
▲(67.65% Upside)
Technical Analysis
Monopar Therapeutics Inc
―
ADC Therapeutics
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
10.36% Insiders
7.55% Mutual Funds
47.67% Other Institutional Investors
23.91% Public Companies and
Individual Investors